ValiRx PLC VAL
LSE · United Kingdom · Health Technology
GBp 0.1500+0.01 (+11.11%)
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
ImmuPharma PLC (AIM:IMM, FRA:25I) has signed up Kymos Group as its bioanalytical partner for diabetes drug Kapiglucagon. That completes the outsourced team needed to file for human trials in the US. ValiRx PLC (AIM:VAL, FRA:EAJF) is set to get a second European patent for its cancer-killing peptide from subsidiary Cytolytix. It's targeting triple negative breast cancer and is in talks with a major pharma company. Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) has drilled some strong copper and silver hits at its Mushima North project in Zambia. Lab results are due in the coming weeks, wit
ValiRX CEO Dr Mark Eccleston joined Steve Darling from Proactive to discuss the company’s progress across its expanding oncology and animal health pipeline as the company advances multiple therapeutic assets through its special purpose vehicle (SPV) strategy. Eccleston said the AIM-listed biotechnology company continued to focus on identifying, evaluating and de-risking promising therapeutic assets before advancing them within dedicated commercial entities. Eccleston said the structure allowed each programme to operate with a specialised management focus while leveraging shared expertise acros
ValiRx, the AIM-listed life sciences company focused on early-stage cancer therapeutics and women's health, has raised up to £1.155 million through a placing, subscription, and planned retail offer at 0.2p per share. The shares fell 17% to 0.2p, matching the issue price, which itself...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.